ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most commonly diagnosed cancer and the second leading cause of cancer-related death for U.S. men. This ...

CivicaScript,® a nonprofit company dedicated to bringing low-cost generic medicines to U.S. consumers, announced today that it has lowered the price of its lead product, Abiraterone Acetate Tablets, ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in metastatic prostate cancer pipeline landscape. It ...

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while reiterating a Buy rating on the stock. Currently trading at $25.72, near its 52-week ...

H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock. Currently trading at $11.

To the best of our knowledge, this is the first study aimed at identifying factors predicting primary NHA resistance. In our experience of everyday clinical practice in an unselected CRPC ...